ARTIVA BIOTHERAPEUTICS INC
ARTV · NASDAQ
Updated at 2026-10-14 09:03:13
- Today's High
- $6.74
- Today’s Low
- $6.23
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $6.92
- Previous Close
- $6.77
- Volume
- 248.58K
- Market Cap
- $330.98M
- P/E Ratio
- --
- EPS
- $-3.43
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 5505 MOREHOUSE DRIVE, SAN DIEGO, CA, UNITED STATES, 92121
- Country
- US
- Listing Date
- 2024-07-19
- Fiscal Year End
- December
- Shares Outstanding
- 48.59M
- CIK
- 0001817241
- Website
- www.artivabio.com
Artiva Biotherapeutics, Inc. is a cutting-edge biotechnology firm dedicated to revolutionizing cancer therapy through its proprietary natural killer (NK) cell platform. With a promising pipeline targeting both hematologic and solid tumors, the company is at the forefront of innovation in the dynamic field of immuno-oncology. Leveraging its commitment to scientific excellence and strategic collaborations, Artiva is strategically positioned to advance its clinical candidates, thereby significantly improving patient outcomes in the fight against cancer. As it progresses through crucial clinical trials, the company's innovative approach holds the potential to reshape cancer treatment paradigms.
Financial Metrics
Revenue
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
Operating Expenses
2026-06-30
$26.89M
2026-03-31
$23.76M
2025-12-31
$21.93M
2025-09-30
$22.89M
Net Income
2026-06-30
-$25M
2026-03-31
-$23.51M
2025-12-31
-$20.77M
2025-09-30
-$21.52M
Net Profit Margin
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
Earnings Per Share
2026-06-30
$-0.63
2026-03-31
$-0.95
2025-12-31
$-0.84
2025-09-30
$-0.88
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$23.64M
2026-03-31
-$22.85M
2025-12-31
-$20.1M
2025-09-30
-$20.86M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Expenses | $26.89M | $23.76M | $21.93M | $22.89M |
| Net Income | -$25M | -$23.51M | -$20.77M | -$21.52M |
| Net Profit Margin | -- | -- | -- | -- |
| Earnings Per Share | $-0.63 | $-0.95 | $-0.84 | $-0.88 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$23.64M | -$22.85M | -$20.1M | -$20.86M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.